Journal
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
Volume 1867, Issue 2, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.bbamcr.2019.118616
Keywords
GSK-3alpha; Cardiometabolic disorder; Heart failure; Cancer; Aging; Neurodegenerative disease; Atherosclerosis
Categories
Funding
- University of Sharjah [VCRG/R.824/2019, VCRG/R.824/2018, VCRG/R.449/2018]
- Canadian Institutes of Health Research Foundation
Ask authors/readers for more resources
Glycogen synthase kinase-3 (GSK-3) is a widely expressed serine/threonine kinase regulates a variety of cellular processes including proliferation, differentiation and death. Mammals harbor two structurally similar isoforms GSK-3 alpha and beta that have overlapping as well as unique functions. Of the two, GSK-3 beta has been studied (and reviewed) in far greater detail with analysis of GSK-3 alpha often as an afterthought. It is now evident that systemic, chronic inhibition of either GSK-3 beta or both GSK-3 alpha/beta is not clinically feasible and if achieved would likely lead to adverse clinical conditions. Emerging evidence suggests important and specific roles for GSK-3 alpha in fatty acid accumulation, insulin resistance, amyloid-beta-protein precursor metabolism, atherosclerosis, cardiomyopathy, fibrosis, aging, fertility, and in a variety of cancers. Selective targeting of GSK-3 alpha may present a novel therapeutic opportunity to alleviate a number of pathological conditions. In this review, we assess the evidence for roles of GSK-3 alpha in a variety of pathophysiological settings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available